Priya P. Mehta

Ahmedabad, UP, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Real-World Evaluation of a Trastuzumab Emtansine Biosimilar (Ujvira®) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer.

Real-World Evaluation of a Trastuzumab Emtansine Biosimilar (Ujvira®) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer.

Journal: Cureus

Published: February 16, 2026

Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.

Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.

Journal: International journal of breast cancer

Published: October 06, 2025

Catastrophic Outcomes: Rapid Multi-Organ Failure from Paraquat Poisoning- A Case Report.

Catastrophic Outcomes: Rapid Multi-Organ Failure from Paraquat Poisoning- A Case Report.

Journal: Nigerian medical journal : journal of the Nigeria Medical Association

Published: July 24, 2025

"Comparative study of gastric aspirate and bronchoalveolar lavage smear with CBNAAT examination for diagnosis of pulmonary tuberculosis in sputum smear negative suspected patients".

"Comparative study of gastric aspirate and bronchoalveolar lavage smear with CBNAAT examination for diagnosis of pulmonary tuberculosis in sputum smear negative suspected patients".

Journal: The Indian journal of tuberculosis

Published: February 20, 2025

Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India.

Evaluation of the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Biosimilar in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: Findings From a Single-Center Retrospective Analysis in India.

Journal: Cureus

Published: December 19, 2024

Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report.

Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report.

Journal: Current drug safety

Published: July 17, 2024

A Case Report on Trastuzumab Emtansine (T-DM1) in a Patient With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer and Brain Metastases: Long-Term Treatment and Survival.

A Case Report on Trastuzumab Emtansine (T-DM1) in a Patient With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer and Brain Metastases: Long-Term Treatment and Survival.

Journal: Cureus

Published: June 30, 2024

Nab-Paclitaxel-Based Systemic Approach to Achieving Complete Remission for Relapsed Stage III Endometrial Carcinoma: Insights From the Indian Subcontinent.

Nab-Paclitaxel-Based Systemic Approach to Achieving Complete Remission for Relapsed Stage III Endometrial Carcinoma: Insights From the Indian Subcontinent.

Journal: Cureus

Published: March 16, 2024

A Case Report on the Efficacy of Trastuzumab Emtansine in a Patient With Human Epidermal Growth Factor Receptor 2 Exon 20-Mutated Adenocarcinoma of the Lung.

A Case Report on the Efficacy of Trastuzumab Emtansine in a Patient With Human Epidermal Growth Factor Receptor 2 Exon 20-Mutated Adenocarcinoma of the Lung.

Journal: Cureus

Published: April 28, 2023

Favorable Outcome and Safety of Neoadjuvant Trastuzumab Emtansine (T-DM1) in a HER2-Positive Early Breast Cancer Patient with Severe Renal Disease on Hemodialysis Ineligible for Conventional Chemotherapy: A Case Report.

Favorable Outcome and Safety of Neoadjuvant Trastuzumab Emtansine (T-DM1) in a HER2-Positive Early Breast Cancer Patient with Severe Renal Disease on Hemodialysis Ineligible for Conventional Chemotherapy: A Case Report.

Journal: Reports (MDPI)

Published: November 18, 2022

Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study.

Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study.

Journal: SAGE open medical case reports

Published: July 14, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026